I received my PhD in Rheumatology, studying the effect of Matrix Metalloproteinases (MMPs) on cartilage destruction, from University of Newcastle upon Tyne in 2003, and moved to Division of Therapeutics & Molecular Medicine, University of Nottingham, to research MMPs in Airway Remodeling until 2006.After that, I joined AstraZeneca Charnwood (2006-2010), working within a GLP/GCP department, developing & validating ligand binding assays and analysing biomarkers in clinical samples, before moving to the AZ Personalised Healthcare & Biomarker group in Gothenburg, Sweden continuing with the challenge of biomarker analysis. In 2015 I joined the newly formed Nucleotide Bioanalysis Group (Gothenburg) providing analytical support to the progression of New Modality (Oligonucleotide) therapeutics in pre-clinical models.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
AstraZeneca | Associate Principal Scientist | Mar 1, 2015 | — | Detail |